{"id":61557,"date":"2015-11-18T22:34:04","date_gmt":"2015-11-19T03:34:04","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=61557"},"modified":"2015-11-18T22:35:27","modified_gmt":"2015-11-19T03:35:27","slug":"pinch-me","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2015\/11\/18\/pinch-me\/","title":{"rendered":"pinch me!&#8230;"},"content":{"rendered":"<table width=\"95%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\" align=\"center\">\n<tr>\n<td>\n<div align=\"justify\" class=\"small\">Nov. 17, 2015<\/div>\n<div align=\"justify\" class=\"middle\"><a href=\"http:\/\/www.ama-assn.org\/ama\/pub\/news\/news\/2015\/2015-11-17-ban-consumer-prescription-drug-advertising.page\" target=\"_blank\">AMA Calls for Ban on Direct to Consumer Advertising of Prescription Drugs and Medical Devices<\/a><\/div>\n<div align=\"justify\" class=\"small\"><strong>For immediate release:<\/strong><\/div>\n<p align=\"justify\" class=\"small\">ATLANTA &ndash;Responding to the billions of advertising dollars being  spent to promote prescription products, physicians at the Interim  Meeting of the American Medical Association (AMA) today adopted new  policy aimed at driving solutions to make prescription drugs more  affordable.<\/p>\n<p align=\"justify\" class=\"small\">Physicians cited concerns that a growing proliferation of ads is  driving demand for expensive treatments despite the clinical  effectiveness of less costly alternatives.<\/p>\n<p align=\"justify\" class=\"small\">&ldquo;Today&rsquo;s vote in support of an advertising ban reflects concerns  among physicians about the negative impact of commercially-driven  promotions,  and the role that marketing costs play in fueling  escalating drug prices,&rdquo; said  AMA Board Chair-elect Patrice A. Harris,  M.D., M.A. &ldquo;Direct-to-consumer advertising also inflates demand for new  and more expensive drugs, even when these drugs may not be appropriate.&rdquo;<\/p>\n<p align=\"justify\" class=\"small\">The United States and New Zealand are the only two countries in the  world that allow direct-to-consumer advertising of prescription drugs.  Advertising dollars spent by drug makers have increased by 30 percent in  the last  two years to $4.5 billion, according to the market research  firm Kantar Media.<\/p>\n<p align=\"justify\" class=\"small\">New AMA policy also calls for convening a physician task force and  launching an advocacy campaign to promote prescription drug  affordability by demanding choice and competition in the pharmaceutical  industry, and greater transparency  in prescription drug prices and  costs.<\/p>\n<p align=\"justify\" class=\"small\">&ldquo;Physicians strive to provide the best possible care to their  patients, but increases in drug prices can impact the ability of  physicians to offer their patients the best drug treatments,&rdquo; said Dr.&nbsp;  Harris. &ldquo;Patient care can be compromised and delayed when prescription  drugs are unaffordable and subject to coverage limitations by the  patient&rsquo;s health plan. In a worst-case scenario, patients forego  necessary treatments when drugs are too expensive.&rdquo;<\/p>\n<p align=\"justify\" class=\"small\">New AMA policy responds to deepened  concerns that anticompetitive  behavior in a consolidated pharmaceutical marketplace has the potential  to increase drug prices. The AMA will encourage actions by federal  regulators to limit anticompetitive behavior by pharmaceutical companies  attempting to reduce competition from generic manufacturers through  manipulation of patent protections and abuse of regulatory exclusivity  incentives.<\/p>\n<p align=\"justify\" class=\"small\">The AMA will also monitor pharmaceutical company mergers and  acquisitions, as well as the impact of such actions on drug prices.  Patent reform is a key area for encouraging greater market-based  competition and new AMA policy will support an appropriate balance  between incentives for innovation on the one hand and efforts to reduce  regulatory and statutory barriers to competition as part of the patent  system.<\/p>\n<p align=\"justify\" class=\"small\">Last month, the Kaiser Family Foundation released a <a target=\"_blank\" href=\"http:\/\/kff.org\/health-costs\/press-release\/prescription-drug-costs-remain-atop-the-publics-national-health-care-agenda-well-ahead-of-affordable-care-act-revisions-and-repeal\/\">report<\/a><img decoding=\"async\" border=\"0\" title=\"External Link\" alt=\"External Link\" style=\"margin-left: 3px; vertical-align: middle;\" src=\"http:\/\/www.ama-assn.org\/resources\/images\/icons\/ico-external.gif\" class=\"linkicon\" \/>  saying that a high cost of prescription drugs remains the public&rsquo;s top  health care priority. In the past few years, prices on generic and  brand-name prescription drugs have steadily risen and experienced a 4.7  percent spike in 2015, according to the Altarum Institute Center for  Sustainable Health Spending.<\/p>\n<div align=\"justify\" class=\"small\">The AMA&rsquo;s new policy recognizes that the promotion of transparency in  prescription drug pricing and costs will help patients, physicians and  other stakeholders understand how drug manufacturers set prices. If  there is greater understanding of the factors that contribute to  prescription drug pricing, including the research, development,  manufacturing, marketing and advertising costs borne by pharmaceutical  companies, then the marketplace can react appropriately.<\/div>\n<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Nov. 17, 2015 AMA Calls for Ban on Direct to Consumer Advertising of Prescription Drugs and Medical Devices For immediate release: ATLANTA &ndash;Responding to the billions of advertising dollars being spent to promote prescription products, physicians at the Interim Meeting of the American Medical Association (AMA) today adopted new policy aimed at driving solutions to [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-61557","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/61557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=61557"}],"version-history":[{"count":5,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/61557\/revisions"}],"predecessor-version":[{"id":61562,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/61557\/revisions\/61562"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=61557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=61557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=61557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}